Shattuck Labs, INC 10-Q quarterly reports

Shattuck Labs, Inc. (STTK) announced positive Phase 1 data for its lead candidate SL-325, demonstrating a favorable safety profile and complete receptor occupancy, while also reporting increased cash reserves from recent financings.

Shattuck Labs, Inc. filed its Q1 2026 10-Q, detailing a net loss of $14.8 million and continued progress in its SL-325 clinical trial, with cash reserves projected to fund operations into 2029.

Shattuck Labs reported a significant reduction in net loss for Q3 and the nine months ended September 30, 2025, driven by decreased R&D and G&A expenses, while securing $45.7 million in a private placement.

Shattuck Labs reports reduced Q2 2025 net loss and R&D expenses, secures a significant private placement of up to $103 million, and plans to initiate Phase 1 clinical trials for its lead candidate SL-325.

Shattuck Labs announces its Q1 2025 financial results, focusing on the advancement of its SL-325 program for inflammatory and immune-mediated diseases.

Shattuck Labs discontinues its SL-172154 program and focuses on its DR3 antagonist program, reporting a net loss of $56.7 million for the first nine months of 2024.

Shattuck Labs reported its second quarter 2024 financial results, highlighting progress in clinical trials and research collaborations.

Shattuck Labs reports a net loss of $18.5 million for the first quarter of 2024, alongside updates on its clinical programs and a new collaboration agreement.